

Jubilant Life Sciences Ltd
(Formerly Jubilant Organosys Ltd.)

Regd. Off: Bhartigram, Gajraula, Dist. Jyotiba Phoolay Nagar-244 223 (U.P.)

Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2011

(' ₹ In Lacs)

STANDALONE RESULTS					CONSOLIDATED RESULTS				
Quarter Ended	Half Year Ended	Year Ended	Particulars		Quarter Ended	Half Year Ended	Year Ended		
September 30 (Unaudited)	September 30 (Unaudited)	March 31 (Audited)			September 30 (Unaudited)	September 30 (Unaudited)	March 31 (Audited)		
2011	2010	2011			2011	2010	2011	2010	2011
62837	54062	124539	Net sales/Income from operations		104808	85697	199237	167659	343340
266	40	439	Other Operating Income		200	131	619	230	883
63103	54102	124978	Total Income		105008	86028	199856	167889	344223
54963	44023	107170	Total expenditure		86282	76131	167486	148684	306812
(2467)	(116)	(4684)	a) (Increase)/Decrease in stock in trade and work in progress		(4522)	876	(8723)	(1905)	(3880)
6065	5446	11569	b) Purchase of traded goods		6554	4551	13139	10314	24007
29893	21054	58348	c) Raw & process materials consumed		36657	27362	70235	55563	112943
2232	2023	5092	d) Stores, spares, chemicals, catalyst & packing material consumed		5113	5068	10985	10453	21188
5349	4882	10693	e) Power & fuel		5822	5368	11823	10521	22404
1801	1393	3064	f) Other manufacturing expenses		2539	1851	4342	3289	6965
5090	4128	9768	g) Staff cost		20603	18081	39579	35778	71842
2921	2475	5689	h) Depreciation		5080	4926	10057	9788	18010
4079	2738	7431	i) Other Expenditure (Selling, general & admin. Expenses-including Exchange loss/Gain)		8446	8048	16049	14923	33333
8140	10079	17808	Operating profit before Other Income & Interest		18726	9897	32370	19205	37411
229	49	464	Other Income		340	424	707	637	1296
8389	10128	18272	Profit before Interest & Exceptional Items		19056	10321	33077	19862	38707
3599	854	6600	Interest (Net)		4969	2476	9307	4433	10506
4770	9274	11672	Profit after Interest but before Exceptional Items		14087	7845	23770	15439	28201
4160	(624)	4428	Exceptional Items		4260	291	4678	2371	4142
610	9898	7244	Profit from Ordinary Activities before tax		9837	7554	19092	13088	24059
110	1024	1355	Tax Expense (Net)		930	260	2446	838	1336
500	8874	5889	Net profit from Ordinary Activities after tax		8907	7294	16646	12250	22723
-	-	-	Extraordinary Items (net of tax expenses)		-	-	-	-	-
-	-	-	Minority Interest		971	(52)	998	(119)	(249)
500	8874	5889	Net profit after Minority Interest		7936	7346	15648	12339	22972
1593	1588	1593	Paid-up share capital (Face value per share ₹ 1)		1593	1588	1593	1588	1593
-	-	-	Reserves (excluding revaluation reserve)		-	-	-	-	-
-	-	-	Earnings per share before and after extraordinary items (Not annualized)		-	-	-	-	-
0.31	5.57	3.69	Basic (₹)		4.98	4.61	9.82	7.78	14.42
0.31	5.04	3.69	Diluted (₹)		4.98	4.17	9.82	7.03	13.04
8134677	83627751	81344677	Public shareholding		8134677	83627751	81344677	83627751	84129115
51.07	52.67	51.07	Number of shares (₹ 1 each)		51.07	52.67	51.07	52.67	52.82
-	-	-	Percentage of shareholding		-	-	-	-	-
-	-	-	Promoters and promoter group Shareholding		-	-	-	-	-
-	-	-	a) Pledged/Encumbered		-	-	-	-	-
6552333	8928300	6552333	Number of shares		6552333	8928300	6552333	8928300	7531333
8.41	11.88	8.41	Percentage of shares (as a % of the total shareholding of promoter and promoter group)		8.41	11.88	8.41	11.88	10.02
4.11	5.62	4.11	Percentage of shares (as a % of the total share capital of the company)		4.11	5.62	4.11	5.62	4.73
-	-	-	b) Non-Encumbered		-	-	-	-	-
71384129	66223724	71384129	Number of shares		71384129	66223724	71384129	66223724	67620691
91.59	88.12	91.59	Percentage of shares (as a % of the total shareholding of promoter and promoter group)		91.59	88.12	91.59	88.12	89.98
44.82	41.71	44.82	Percentage of shares (as a % of the total share capital of the company)		44.82	41.71	44.82	41.71	42.45

Notes:

1. During the quarter Cadista Holdings Inc. USA, our step down subsidiary where the company holds 82.38% equity, carrying on its generic business through a wholly owned subsidiary, Jubilant Cadista Pharmaceuticals Inc. USA, was registered with the Securities and Exchange Commission (SEC) of United States of America, under Section 12 (g) of the Securities and Exchange Control Act, United States of America.
2. The Company's operates under one reportable segment viz. Pharmaceuticals and Life Sciences Products and Services (PLSPS).
3. During the quarter the Company has opted for cash flow hedge accounting, in respect of certain transactions, under AS 30 issued by the Institute of Chartered Accountants of India. Accordingly, foreign exchange translation loss of ₹ 1483 lacs has been debited to hedging reserve account.
4. Exceptional items include :
 - i) Amortization of Foreign Currency Monetary Item Translation Difference Account(loss/gain) ₹ 2637 lacs (Consolidated ₹ 2637 lacs) for Q2-FY 2012 and ₹ 2851 lacs (Consolidated ₹ 2851 lacs) for H1-FY 2012.
 - ii) Mark to Market in respect of Currency and interest rate swap contracts outstanding at the period end resulting in loss/gain amounting to ₹ 1523 lacs (Consolidated ₹ 1623 lacs) for Q2 FY 2012 and ₹ 1577 lacs (Consolidated ₹ 1827 lacs) for H1-FY 2012.
 5. Tax Expenses(Net) is after considering the MAT Credit Entitlement ₹ 1464 lacs (Consolidated ₹ 1737 lacs) for H1-FY 2012.
 6. The Compensation Committee of the Board on 24th October, 2011, has granted 862461 options to eligible Employees/Directors of the Company and its subsidiaries as per JIL Employee Stock Option Plan, 2011. Each option shall entitle the holder to acquire 1 equity share of ₹ 1 each fully paid at ₹ 200.05, being the market price as per SEBI guidelines. There is no dilution envisaged on account of this grant.
 7. Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New -23, Disposals -23, Closing Balance - Nil.
 8. The results for the corresponding quarter/six months has been recasted to give effect to the Scheme of Amalgamation & Demerger approved by Hon'ble High Court of Judicature, Allahabad during FY 2011 with effect from 1st April 2010.
 9. Previous year / periods figures have been regrouped/reclassified wherever necessary.
 10. The above unaudited results were, subjected to limited review by the auditors of the Company, reviewed by the Audit Committee at its meeting held on 31st October, 2011 and approved by the Board of Directors at its meeting held on 1st November, 2011.

Place : Noida

Dated : 1st November, 2011

For Jubilant Life Sciences Ltd.



Shyam S Bhartia

Chairman & Managing Director

Jubilant Life Sciences Ltd.
(Formerly Jubilant Organosys Ltd.)

Regd. Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar-244 223 (U.P.)

Statement of Assets And Liabilities

(₹ in lacs)

STAND ALONE			CONSOLIDATED		
As at September 30 (Unaudited)	As at March 31 (Audited)	Particulars	As at September 30 (Unaudited)	As at March 31 (Audited)	
2011	2010		2011	2010	
1593	1588	Share holders Funds	1593	1588	1593
212551	204344	a) Capital	236348	203941	215634
-	-	b) Reserves and Surplus	6068	3923	4181
266216	181296	Minority Interest	361736	287081	388416
-	-	Loan from Banks, Institutions and FCCB's	-	4621	4036
19907	21877	Loan from Customers	23087	23631	21070
		Deferred Tax Liabilities(Net)			
500267	409105	18990	628832	524785	634930
		TOTAL			
212770	179191	Fixed Assets	499566	437630	466881
8035	-	Investments-In Liquid Funds	8035	2484	-
190237	177119	Investments-Others	3634	3278	3275
-	-	Deferred Tax Assets(Net)	6695	4421	3950
5274	17	Foreign Currency Monetary Items Translation Difference Account(FCMITDA)	5274	1141	-
49847	34071	Current Assets , Loans and Advances			
30978	35275	a) Inventories	86013	61670	69128
895	4837	b) Sundry Debtors	58225	53968	52045
-	-	c) Cash and Bank balances	10115	11621	104569
77034	59298	d) Other Current Assets	-	-	-
		e) Loans and Advances	63878	52454	56537
59998	37383	Less : Current Liabilities and Provisions			
14805	43320	a) Liabilities	91349	58955	78614
-	-	b) Provisions	21254	44927	42841
		Miscellaneous Expenditure (Not Written Off or Adjusted)	-	-	-
500267	409105	TOTAL	628832	524785	634930